80 research outputs found
AAN-EFNS guidelines on trigeminal neuralgia management
No full textSeveral issues regarding diagnosis, pharmacological treatment, and surgical treatment of trigeminal neuralgia (TN) are still unsettled. The American Academy of Neurology and the European Federation of Neurological Societies launched a joint Task Force to prepare general guidelines for the management of this condition. After systematic review of the literature the Task Force came to a series of evidence-based recommendations. In patients with TN MRI may be considered to identify patients with structural causes. The presence of trigeminal sensory deficits, bilateral involvement, and abnormal trigeminal reflexes should be considered useful to disclose symptomatic TN, whereas younger age of onset, involvement of the first division, unresponsiveness to treatment and abnormal trigeminal evoked potentials are not useful in distinguishing symptomatic from classic TN. Carbamazepine (stronger evidence) or oxcarbazepine (better tolerability) should be offered as first-line treatment for pain control. For patients with TN refractory to medical therapy early surgical therapy may be considered. Gasserian ganglion percutaneous techniques, gamma knife and microvascular decompression may be considered. Microvascular decompression may be considered over other surgical techniques to provide the longest duration of pain freedom. The role of surgery versus pharmacotherapy in the management of TN in patients with multiple sclerosis remains uncertain. © 2008 The Author(s)
Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies.
No full textChronic Migraine
No full textThis narrated powerpoint is a review of Chronic Migraine. This includes a review of the pathophysiology of migraine and what contributes to the chronicity of migraine. Treatments of chronic migraine are also reviewed.Hutton, E. J., & Matharu, M. (2021). OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy. Journal of clinical medicine, 10(13), 2898. https://doi.org/10.3390/jcm10132898. Shibata Y. (2022). Migraine Pathophysiology Revisited: Proposal of a New Molecular Theory of Migraine Pathophysiology and Headache Diagnostic Criteria. International journal of molecular sciences, 23(21), 13002. https://doi.org/10.3390/ijms232113002. Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., Ashman, E., & Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (2012). Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology, 78(17), 1337-1345. https://doi.org/10.1212/WNL.0b013e3182535d2
500 OPEN-LABEL, OPEN-ENDED STUDY OF THE SAFETY OF DICLOFENAC TOPICAL SOLUTION FOR MANAGEMENT OF OSTEOARTHRITIS: CHARACTERIZATION OF APPLICATION-SITE ADVERSE EVENTS
No full text499 OPEN-LABEL, OPEN-ENDED STUDY OF THE SAFETY OF DICLOFENAC TOPICAL SOLUTION FOR MANAGEMENT OF OSTEOARTHRITIS: CHARACTERIZATION OF GASTROINTESTINAL ADVERSE EVENTS
No full textTopical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury
No full text(397) Improvement in pain severity category following treatment with pregabalin in patients with fibromyalgia
No full text(399) Small Fiber Polyneuropathy: A Big Clue to Etiology and Management of Chronic Pelvic Pain (CPP)
No full text
Validity testing of patient objections to acceptance of tamper-resistant opioid formulations
No full text- …
